3D Renal Tissue Chip Models to Evaluate Nephrotoxic Effects of Drugs

用于评估药物肾毒性作用的 3D 肾组织芯片模型

基本信息

  • 批准号:
    10249974
  • 负责人:
  • 金额:
    $ 3.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The current pathway for drug discovery is associated with costs of $2.55 billion and between 10-15 years of development for a single drug to reach the market. The challenges in predicting drug toxicities and efficacies are attributed to inherent species differences in drug-metabolizing enzyme activities and cell-type-specific sensitivities to toxicants. Organs-on-a-chip are an emerging technology in disease modeling and screening therapeutics to address discrepancies between animal models and human clinical trials. They utilize tissue engineering, fluid mechanics, and biomaterials to replicate in vivo architectures and functions of complex organs and tissues. The renal proximal tubule (PT) in vivo is exposed to fluid flow and mechanical stress (pressure, stretch, shear) and these stimuli play an important role in maintaining cellular phenotype and homeostasis. Currently, available prototypes fall short of replicating the in vivo environment because they often fail to mimic the physiological forces. Therefore, these models have had limited success in predicting drug-induced nephrotoxicity. In this proposal, we will bioengineer and evaluate a dynamic platform of the PT and study the effects of drugs and tubular dysfunction to establish its potential for translational research. Human renal proximal tubule cells (hRPTECs) will be cultured within gelatin methacryloyl (GelMA) hydrogels under physiological shear and pressure. These devices will also incorporate the diversity in the patient population by using hRPTECs from multiple donors to determine the impact of age, sex, and racial differences on nephrotoxicity effects. Drugs will be classified based on their nephrotoxic risk (high, intermediate, and low) and the platform will incorporate automated readouts to reflect cellular function and viability. Together, this will help investigate more accurate pharmacological and pathological responses and to determine the utility of in vitro perfusion models. Secondly, a more complex and novel bioengineered platform will be developed. This design contains a 3D PT tubule and 3D vascular vessels surrounded by pericyte vascular networks. The platform will then be subjected to physiological shear stress and pressure to demonstrate the flow loop can accurately mimic cellular organization, establishment of tight junctions, maintenance of barrier function, and selective transport as seen in vivo. This device composes of a co-culture of hRPTECs, human umbilical vein endothelial cells (hUVECs), and human dermal fibroblasts (hDF) within a GelMA hydrogel to model an environment where both reabsorption and secretion functions are replicated. Lastly, this proposal investigates the translational potential of PT tissue chips through demonstration of a PT diabetic nephropathy model and engineering multi-well PTs to facilitate high- throughput studies. The organ-on-a-chip developed in this study will provide an enabling technology that has broad applications in basic and translational research to model disease states, study interactions with other tissue chips, and accurately predict drug toxicity.
项目概要 目前的药物发现途径需要 25.5 亿美元的成本和 10 至 15 年的时间 开发单一药物以进入市场。预测药物毒性和功效的挑战是 归因于药物代谢酶活性和细胞类型特异性的固有物种差异 对毒物的敏感性。器官芯片是疾病建模和筛查的新兴技术 解决动物模型和人体临床试验之间差异的治疗方法。他们利用组织 工程、流体力学和生物材料来复制复杂器官的体内结构和功能 和纸巾。体内肾近曲小管 (PT) 暴露于液体流动和机械应力(压力、 拉伸、剪切),这些刺激在维持细胞表型和稳态方面发挥着重要作用。 目前,可用的原型无法复制体内环境,因为它们通常无法模仿 生理力量。因此,这些模型在预测药物诱导的 肾毒性。在本提案中,我们将对 PT 的动态平台进行生物工程和评估,并研究 药物和肾小管功能障碍的影响,以确定其转化研究的潜力。人肾近端 肾小管细胞 (hRPTEC) 将在生理剪切力下在明胶甲基丙烯酰 (GelMA) 水凝胶中培养 和压力。这些设备还将通过使用 hRPTEC 来整合患者群体的多样性 多个捐赠者以确定年龄、性别和种族差异对肾毒性影响的影响。药物会 根据肾毒性风险(高、中、低)进行分类,该平台将纳入 自动读数反映细胞功能和活力。总之,这将有助于更准确地调查 药理学和病理学反应并确定体外灌注模型的效用。第二, 将开发更复杂和新颖的生物工程平台。该设计包含 3D PT 小管和 被周细胞血管网络包围的 3D 血管。随后该平台将受到 生理剪切应力和压力,以证明流动回路可以准确地模拟细胞组织, 建立紧密连接、维持屏障功能以及体内选择性运输。这 该装置由 hRPTEC、人脐静脉内皮细胞 (hUVEC) 和人脐静脉内皮细胞 (hUVEC) 的共培养物组成。 GelMA 水凝胶内的真皮成纤维细胞 (hDF) 可以模拟重吸收和 分泌功能被复制。最后,该提案研究了 PT 组织芯片的转化潜力 通过演示 PT 糖尿病肾病模型并设计多孔 PT 来促进高 吞吐量研究。本研究开发的器官芯片将提供一种使能技术 在基础和转化研究中广泛应用,以模拟疾病状态、研究与其他疾病的相互作用 组织芯片,​​准确预测药物毒性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leslie Donoghue其他文献

Leslie Donoghue的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leslie Donoghue', 18)}}的其他基金

3D Renal Tissue Chip Models to Evaluate Nephrotoxic Effects of Drugs
用于评估药物肾毒性作用的 3D 肾组织芯片模型
  • 批准号:
    10471996
  • 财政年份:
    2020
  • 资助金额:
    $ 3.73万
  • 项目类别:

相似国自然基金

RIP3/MLKL/GSDMD程序性调控坏死与炎症正反馈环路反应在急性肾损伤慢性化中的作用机制研究
  • 批准号:
    81870472
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    面上项目
Gasdermin家族蛋白介导的细胞程序性坏死在急性肾衰竭中的作用
  • 批准号:
    81700596
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
基于光学相干成像评估移植肾脏功能研究
  • 批准号:
    61675044
  • 批准年份:
    2016
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
人参皂苷Rg1联合HIF-1α基因修饰的人羊膜间充质干细胞对小鼠急性肾小管坏死模型协同治疗效果及机制探讨
  • 批准号:
    81460136
  • 批准年份:
    2014
  • 资助金额:
    47.0 万元
  • 项目类别:
    地区科学基金项目
Wnt信号通路对肾小管上皮细胞极性的影响
  • 批准号:
    30971377
  • 批准年份:
    2009
  • 资助金额:
    31.0 万元
  • 项目类别:
    面上项目

相似海外基金

Regulation of Lymphatic and Vascular Remodeling in Acute Kidney Injury
急性肾损伤中淋巴和血管重塑的调节
  • 批准号:
    10750349
  • 财政年份:
    2023
  • 资助金额:
    $ 3.73万
  • 项目类别:
Patient-Derived Kidney Organoids For Modeling Kidney Injury
用于肾损伤建模的患者肾脏类器官
  • 批准号:
    10663719
  • 财政年份:
    2023
  • 资助金额:
    $ 3.73万
  • 项目类别:
Unanticipated roles of C5aR1 Signaling Leading from Acute to Chronic Kidney Disease
C5aR1 信号转导从急性肾病到慢性肾病的意外作用
  • 批准号:
    10591053
  • 财政年份:
    2023
  • 资助金额:
    $ 3.73万
  • 项目类别:
Rac1 and the actin cytoskeleton in renal tubular repair
Rac1 和肌动蛋白细胞骨架在肾小管修复中的作用
  • 批准号:
    10739610
  • 财政年份:
    2023
  • 资助金额:
    $ 3.73万
  • 项目类别:
Importance of cell-matrix interactions in kidney repair after acute kidney injury
细胞-基质相互作用在急性肾损伤后肾脏修复中的重要性
  • 批准号:
    10585440
  • 财政年份:
    2023
  • 资助金额:
    $ 3.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了